Martin P Vacanti

This inventor holds 13 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Vbi Technologies, LLC, Vcell Therapeutics, Inc., Children's Medical Center Corporation. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin P Vacanti. Retrieved from https://idiyas.com/inventor/martin-p-vacanti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 46.2

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 403(Granted Patents)

Location History:

Westborough, MA (US) (2001 - 2009)
Manhattan, KS (US) (2008 - 2024)

Company Filing History:

10 out of 10

Vbi Technologies, LLC

patents

2 out of 3

Vcell Therapeutics, Inc.

patents

1 out of 1,074

Children's Medical Center Corporation

patents

4. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11963977 - Generating pluripotent cells de novo (2024-04-23),

2. 11028363 - Subpopulations of spore-like cells and uses thereof (2021-06-08),

3. 9999638 - Subpopulations of spore-like cells and uses thereof (2018-06-19),

4. 9663765 - Subpopulations of spore-like cells and uses thereof (2017-05-30),

5. 9145545 - Subpopulations of spore-like cells and uses thereof (2015-09-29),

6. 8551775 - Subpopulations of spore-like cells and uses thereof (2013-10-08),

7. 7964394 - Spore-like cells and uses thereof (2011-06-21),

8. 7575921 - Spore-like cells and uses thereof (2009-08-18),

9. 7560275 - Compositions and methods for generating skin (2009-07-14),

10. 7470425 - Population of undifferentiated neural, endocrine or neuroendocrine cells in a hydrogel support (2008-12-30),

11. 7319035 - Biological scaffolding material (2008-01-15),

12. 7060492 - Isolation of spore-like cells from tissues exposed to extreme conditions (2006-06-13),

13. 6171610 - Guided development and support of hydrogel-cell compositions (2001-01-09),

Title: Innovations and Contributions of Martin P Vacanti

Introduction

Martin P Vacanti is a prominent inventor based in Manhattan, Kansas, known for his significant contributions to the field of cellular biology and regenerative medicine. With a total of 13 patents to his name, Vacanti has made remarkable strides in the development of technologies that advance our understanding of pluripotent cells and their applications in medical treatments.

Latest Patents

Among his latest patents, Vacanti has developed methods for generating pluripotent cells de novo. This technology focuses on causing a cell to assume a more pluripotent state without the introduction of foreign genetic material. Another notable patent involves subpopulations of spore-like cells, which express specific cell surface and gene expression markers. These cells can be purified and induced to differentiate into various cell types, potentially treating deficiencies in tissues such as the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.

Career Highlights

Throughout his career, Vacanti has worked with several innovative companies, including Vbi Technologies, L.L.C. and Vcell Therapeutics, Inc. His work has been instrumental in pushing the boundaries of what is possible in cellular therapies and regenerative medicine.

Collaborations

Vacanti has collaborated with notable individuals in his field, including Charles Alfred Vacanti and Joseph P Vacanti. These collaborations have further enriched his research and contributed to the advancement of cellular technologies.

Conclusion

Martin P Vacanti's innovative work and numerous patents highlight his significant impact on the field of regenerative medicine. His contributions continue to pave the way for new treatments and therapies that can improve patient outcomes.

Profile summary based on public USPTO records.